These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29512464)

  • 1. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
    Jamwal S; Kumar P
    Curr Neuropharmacol; 2019; 17(2):165-175. PubMed ID: 29512464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Huntington chorea. Review of the most recent aspects of research].
    Albano C; Farinini D; Tassinari T; Caponnetto C; Bacigalupo F
    Riv Neurol; 1985; 55(4):247-55. PubMed ID: 2997905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neurotransmitters in Huntington chorea (review)].
    Barkhatova VP; Larskiĭ EG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):444-50. PubMed ID: 2581405
    [No Abstract]   [Full Text] [Related]  

  • 4. [Progresses in the study of unbalance of basal ganglia neurotransmitters in Parkinson's disease].
    Sun ZL; Jia J; Yu F
    Sheng Li Ke Xue Jin Zhan; 2011 Dec; 42(6):427-30. PubMed ID: 22363981
    [No Abstract]   [Full Text] [Related]  

  • 5. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
    Gill JS; Jamwal S; Kumar P; Deshmukh R
    Pharmacol Rep; 2017 Apr; 69(2):306-313. PubMed ID: 28178592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huntington's disease: pathogenesis to animal models.
    Kumar P; Kalonia H; Kumar A
    Pharmacol Rep; 2010; 62(1):1-14. PubMed ID: 20360611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.
    Creed RB; Menalled L; Casey B; Dave KD; Janssens HB; Veinbergs I; van der Hart M; Rassoulpour A; Goldberg MS
    Neuroscience; 2019 Jun; 409():169-179. PubMed ID: 31029729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease.
    Raj K; Gupta GD; Singh S
    Drug Chem Toxicol; 2022 Sep; 45(5):2097-2108. PubMed ID: 34210222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical neuroanatomy of the basal ganglia--normal and in Parkinson's disease.
    Hornykiewicz O
    J Chem Neuroanat; 2001 Jul; 22(1-2):3-12. PubMed ID: 11470551
    [No Abstract]   [Full Text] [Related]  

  • 11. Chorea.
    Klawans HL
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):536-40. PubMed ID: 2445458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
    Alfinito PD; Wang SP; Manzino L; Rijhsinghani S; Zeevalk GD; Sonsalla PK
    J Neurosci; 2003 Nov; 23(34):10982-7. PubMed ID: 14645494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice.
    Nicniocaill B; Haraldsson B; Hansson O; O'Connor WT; Brundin P
    Eur J Neurosci; 2001 Jan; 13(1):206-10. PubMed ID: 11135020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurochemical substrates of rigidity and chorea in Huntington's disease.
    Storey E; Beal MF
    Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocannabinoid system as a target for the treatment of motor dysfunction.
    Fernández-Ruiz J
    Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease.
    Sepers MD; Raymond LA
    Drug Discov Today; 2014 Jul; 19(7):990-6. PubMed ID: 24603212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal dopamine and homovanillic acid in Huntington's disease.
    Reynolds GP; Garrett NJ
    J Neural Transm; 1986; 65(2):151-5. PubMed ID: 2939198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunctional striatal dopamine signaling in Huntington's disease.
    Koch ET; Raymond LA
    J Neurosci Res; 2019 Dec; 97(12):1636-1654. PubMed ID: 31304622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss.
    Kish SJ; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Ann Neurol; 1986 Jul; 20(1):26-31. PubMed ID: 2874765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
    Schülke JP; Brandon NJ
    Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.